Find information on common issues.
Ask questions and find answers from other users.
Suggest a new site feature or improvement.
Check on status of your tickets.
Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials. More information on Nanomedicine can be found here.
Soft, Biocompatible Optoelectronic Interfaces to the Brain
08 Jun 2017 | | Contributor(s):: John A. Rogers
In this talk, we will describe foundational concepts in physics and materials science for these types of technologies, in 1D, 2D and 3D architectures. Examples in system level demonstrations include experiments on freely moving animals with ‘cellular-scale’, injectable optofluidic...
Tissue-Level Communication Through Patterning Of Intercellular Ca2+ Wave Dynamics
22 Nov 2016 | | Contributor(s):: Jeremiah J. Zartman
Here we characterize periodic intercellular Ca2+ waves (ICWs) in a model organ system of epithelial growth and patterning—the Drosophila wing imaginal disc. We developed a novel regulated environment for micro-organs (REM-Chip) device that enable a broad range of genetic, chemical and...
[Illinois] Translational Nanomedicine from Drug Discovery to Preclinical Studies
10 Nov 2015 | | Contributor(s):: Dipanjan Pan
[Illinois] Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering
26 Aug 2014 | | Contributor(s):: Dipanjan Pan
[Illinois] Plasmonic Engineering in Nanomedicine
28 Apr 2014 | | Contributor(s):: Srikanth Singamaneni
Plasmonics involves the control of light at the nanoscale using surface plasmons. One particular area where plasmonics is expected to make an enoromous impact is the field of life sciences, with applications in bioimaging, biosensing, and targted and externally-triggered therapy. In the first...
Application of Dynamic Light Scattering in the Physicochemical Characterization of Natural and Engineered Nanoparticles
20 Apr 2012 | | Contributor(s):: Trisha Eustaquio
This presentation will highlight the use of dynamic light scattering (DLS), which measures the hydrodynamic size of nanoparticles in suspension, in characterizing specific examples of engineered and natural nanoparticles. In terms of engineered nanoparticles, the role of nanoparticle size in...
The Importance of Zeta Potential for Drug/Gene Delivery in Nanomedicine
11 Apr 2012 | | Contributor(s):: James Leary
Finding a Needle in a Haystack: Nanobarcoding for Single Nanoparticle Detection in in vitro and ex vivo Nanomedical Biodistribution Studies
14 Feb 2012 | | Contributor(s):: Trisha Eustaquio
Determination of the fate of administered nanoparticles in a biological system, or nanoparticle biodistribution, is critical in evaluating a nanoparticle formulation for nanomedical purposes. Unlike their small-molecule drug antecedents, nanoparticles pose unique challenges in the design of...
Illinois Nano EP Seminar Series Spring 2011: Interfacing Engineering, Biology, and Medicine at the Micro and Nano Scale
13 Dec 2011 | | Contributor(s):: Rashid Bashir
In this talk, we will present an overviewof our work in Silicon-Based BioMEMS and Bionanotechnology and discuss the state of the art and thefuture challenges and opportunities. We will review a range of projects in our group focused towardsdeveloping rapid detection of biological entities and...
KIST/PU Nanostructured Heparin Derivatives as an Angiogenesis Inhibitor
07 Dec 2011 | | Contributor(s):: Youngro Byun
Although low molecular weight heparin (LMWH) has been known to regulate angiogenesis, tumor growth and metastasis, the administration of heparin for treating cancer is limited in clinical application due to its unsatisfactory therapeutic effects and a strong anticoagulant activity, which induces...
KIST/PU The Professor’s Challenge: To commercialize or not, that is the question?
06 Dec 2011 | | Contributor(s):: J. Paul Robinson
Outline:Outline the Professors DilemmaShow what the normal criteria for research project direction isDiscuss the Corporate perspectiveDiscuss an example of failed innovationDemonstrate how time can impact an innovative ideaConclusions
KIST/PU Designing a Research Program Around Unmet Clinical Needs
06 Dec 2011 | | Contributor(s):: Alyssa Panitch
KIST/PU Theragnosis – A New Paradigm of Personalized Medicine
06 Dec 2011 | | Contributor(s):: Ick Chan Kwon
Companion Diagnosis, based on pharmacogenomics, has been recognized as one of most important key representatives of personalized medicine. However, Companion Diagnosis does not provide any clues in developing new ways of therapeutics but it only provides a best choice of drugs based on given...
Illinois BioNanotechnology Seminar Series Fall 2011: Precisely Size Controlled Drug-silica Nanoconjugate for Cancer Therapy
05 Dec 2011 | | Contributor(s):: Li Tang
Drug delivery nanomedicine, exemplified by micelles and nanoparticles roughly in the size range of 1-200 nm, have attracted much interest in the past 2-3 decades as alternative modalities for cancer treatment. The size of these drug delivery vehicles has been strongly correlated with their in...
Illinois BioNanotechnology Seminar Series Fall 2011: Directed Blood Vessel Growth Using an Angiogenic Microfiber/Microparticle Composite Patch
05 Dec 2011 | | Contributor(s):: Ross J DeVolder
Therapeutic angiogenesis has emerged as a promising strategy to treat various acute and chronic vascular diseases, and to enhance tissue repair and regeneration. Common revascularization therapies include the administration of angiogenic factors, such as vascular endothelial growth factor...
Illinois BioNanotechnology Seminar Series Fall 2011: Deconvolving Stiffness in MEMS Pedestal Cell Mass Measurements
05 Dec 2011 | | Contributor(s):: Elise Corbin
The complex relationships between a cell's behavior and the physical properties of both itself and its environment have long been of interest. Specifically, the understanding the mechanisms through which a cell's physical properties influence cell growth, cell differentiation, cell cycle...
BME 695L Special Lecture 4: Atomic Force Microscopy (AFM) for Nanomedical Systems (cells and nanoparticles)
02 Dec 2011 | | Contributor(s):: Helen McNally
Guest lecturer: Helen McNally
BME 695L Special Lecture 3: In vivo Model Systems to Study Nanomedical Approaches to Cancer Detection and Intervention
02 Dec 2011 | | Contributor(s):: Deborah W Knapp
Guest lecturer: Deborah Knapp.
BME 695L Lecture 15: GMP and Issues of Quality Control Manufacture of Nanodelivery Systems
02 Dec 2011 | | Contributor(s):: James Leary
See references below for related reading.15.1 Overview15.1.1 What does cGMP mean?15.1.2 Why GMP? Controlling processes means more predictable...
BME 695L Lecture 16: FDA and EPA Regulatory Issues
See references below for related reading.16.1 Introduction and overview16.1.1 How does the FDA think about nanomedical systems?16.1.2 The 2006 Nanotechnology Task Force16.2 Some...